We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Stock Moves -0.24%: What You Should Know
Read MoreHide Full Article
In the latest trading session, Gilead Sciences (GILD - Free Report) closed at $76.24, marking a -0.24% move from the previous day. This move outpaced the S&P 500's daily loss of 0.55%. Meanwhile, the Dow lost 0.68%, and the Nasdaq, a tech-heavy index, lost 1.16%.
Coming into today, shares of the HIV and hepatitis C drugmaker had gained 5.05% in the past month. In that same time, the Medical sector gained 0.81%, while the S&P 500 gained 0.37%.
Investors will be hoping for strength from GILD as it approaches its next earnings release, which is expected to be October 25, 2018. On that day, GILD is projected to report earnings of $1.62 per share, which would represent a year-over-year decline of 28.63%. Our most recent consensus estimate is calling for quarterly revenue of $5.38 billion, down 17.31% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.58 per share and revenue of $21.55 billion, which would represent changes of -25.57% and -17.47%, respectively, from the prior year.
Any recent changes to analyst estimates for GILD should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. GILD is currently a Zacks Rank #3 (Hold).
In terms of valuation, GILD is currently trading at a Forward P/E ratio of 11.64. For comparison, its industry has an average Forward P/E of 31.63, which means GILD is trading at a discount to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 85, putting it in the top 33% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Stock Moves -0.24%: What You Should Know
In the latest trading session, Gilead Sciences (GILD - Free Report) closed at $76.24, marking a -0.24% move from the previous day. This move outpaced the S&P 500's daily loss of 0.55%. Meanwhile, the Dow lost 0.68%, and the Nasdaq, a tech-heavy index, lost 1.16%.
Coming into today, shares of the HIV and hepatitis C drugmaker had gained 5.05% in the past month. In that same time, the Medical sector gained 0.81%, while the S&P 500 gained 0.37%.
Investors will be hoping for strength from GILD as it approaches its next earnings release, which is expected to be October 25, 2018. On that day, GILD is projected to report earnings of $1.62 per share, which would represent a year-over-year decline of 28.63%. Our most recent consensus estimate is calling for quarterly revenue of $5.38 billion, down 17.31% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.58 per share and revenue of $21.55 billion, which would represent changes of -25.57% and -17.47%, respectively, from the prior year.
Any recent changes to analyst estimates for GILD should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. GILD is currently a Zacks Rank #3 (Hold).
In terms of valuation, GILD is currently trading at a Forward P/E ratio of 11.64. For comparison, its industry has an average Forward P/E of 31.63, which means GILD is trading at a discount to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 85, putting it in the top 33% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.